This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today presented additional data on Vascepa® (icosapent ethyl) and its effect on lipoprotein particle concentration from the Phase 3 ANCHOR study at the National Lipid Association (NLA) 2013 Annual Scientific Session in Las Vegas, Nevada.
The data presentation titled, "Effects of Icosapent Ethyl on Lipoprotein Particle Concentration and the Fatty Acid Desaturation Index in Statin-treated Patients with Persistent High Triglycerides (the ANCHOR Study)", reported that Vascepa 4 g/day, when added to optimized statin therapy for 12 weeks, significantly reduced median particle concentrations of total very-low-density lipoprotein (VLDL) by 12.2%, total low-density lipoprotein (LDL) by 7.7%, and small LDL particles by 13.5% across the 12 week treatment period, compared with placebo.
The ANCHOR study, authored by Christie M. Ballantyne, M.D. and colleagues, investigated Vascepa as a treatment for high triglycerides (≥200 and <500mg/dL) in 702 patients with mixed dyslipidemia (two or more lipid disorders) on optimized background statin therapy who were at LDL-C (low-density lipoprotein cholesterol) goal, and who were also at high risk of cardiovascular disease. The original results, which were presented at the American Heart Association in 2011, highlighted that Vascepa 4 g/day demonstrated a significant median reduction in triglyceride levels, the primary endpoint, of 21.5%, as well as a significant median reduction in low-density lipoprotein cholesterol (LDL-C) of 6.2%, compared to the group of patients on optimized statin therapy and placebo.
Amarin also presented, or provided financial support for, research surrounding three additional topics at this year's NLA meeting, including:
pharmacokinetic data showing the lack of drug-drug interaction when Vascepa was administered with atorvastatin, a commonly prescribed cholesterol lowering medication
pharmacokinetic data showing the lack of drug-drug interaction when Vascepa was administered with warfarin, a commonly prescribed anticoagulant medication
eicosapentaenoic acid (EPA) and its potential inhibition of the formation of membrane cholesterol crystalline domains
About Vascepa® (icosapent ethyl) capsules
Vascepa® (icosapent ethyl) capsules, known in scientific literature as AMR101, is a patented, pure-EPA omega-3 prescription product in a 1 gram capsule.